RAD 2025: What You May Have Missed
Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.
Expanding Access to Atopic Dermatitis Treatments for Children: A Conversation with Elizabeth Swanson, MD
At RAD 2025, pediatric dermatologist Elizabeth Swanson, MD, discussed the value of focused AD education and anticipated label expansions for several treatments.
Q&A: JAK Inhibitor Safety in Context and the Rich Atopic Dermatitis Pipeline, with Leon Kircik, MD
RAD 2025: Renowned AD investigator Kircik provides the history behind the class-wide black box warning, highlights JAK inhibitor efficacy, and toplines exciting AD research.
Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhD
At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.
A Close Look at Flexible Dosing Strategies for Atopic Dermatitis in Adults with Raj Chovatiya, MD, PhD, MSCI
RAD 2025: Chovatiya toplines shifts in dosing strategies for topical, oral, and injectable AD therapy observed in both clinical trials and clinical practice.
Pediatric Atopic Dermatitis: Navigating Patient, Provider, Caregiver Connection with Peter Lio, MD
RAD 2025. Peter Lio, MD, shares details from his presentation on shared decision making when treating children with atopic dermatitis.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.
Flexible Dosing in in Atopic Dermatitis Treatment: Notes on Real-World Use with Raj Chovatiya, MD, PhD, MSCI
RAD 2025: Chovatiya spoke at RAD about the need to better understand how treatments for AD are being used in the real world, after symptoms subside and skin signs clear.
2025 ACOG Annual Clinical & Scientific Meeting: What You May Have Missed
From primary care management of heavy menstrual bleeding to postpartum depression screening, find out what you may have missed at ACOG 2025.
Q&A: Cumulative Life Course Impairment of Atopic Dermatitis with Mona Shahriari, MD
RAD 2025: As expert dermatologist Shahriari explains it, eczema may be just another rash on your schedule but for a patient, it could be the reason they don't leave the house.
Chronic Hand Eczema: Clinical Insights and Future Directions from RAD 2025
RAD 2025: Explore expert insights on chronic hand eczema, its differences from atopic dermatitis, and emerging treatments in this informative video series.
Upadacitinib Shows Real-World Efficacy in Bio-Naïve, Bio-Experienced Adults with Atopic Dermatitis in New Study
RAD 2025: Many adults achieved optimal treatment targets with upadacitinib after 6 months, regardless of prior biologic therapy, according to new late-breaking data.
Q&A: Managing Chronic Itch With Renowned Investigator Gil Yosipovitch, MD
RAD 2025: World expert on the pathophysiology of itch Gil Yosipovitch, MD, answers questions on the disease of chronic itch and on the expanding options for targeted treatment.
Beyond the Rash: Collaborative Insights on Pediatric Atopic Dermatitis
RAD 2025: Lisa Swanson, MD, shares insights on pediatric atopic dermatitis, addressing questions from both a dermatologist's and an allergist's perspective.
Persistent Underutilization of Systemic Therapy for Atopic Dermatitis Highlights Gap Between Need and Care
RAD 2025: Mobile health data reveal a troubling decline in systemic treatment for moderate-to-severe atopic dermatitis, underscoring issues in access and clinical inertia.
Dupilumab Monotherapy Improves AD Severity and Pigmentation in People With Skin of Color
Dupilumab monotherapy showed significant improvements in atopic dermatitis symptoms in patients with skin of color, according to late-breaking data presented at RAD 2025.
Long-Term Data on Nemolizumab Demonstrate Safety, Sustained Symptom Improvement in Patients With Atopic Dermatitis up to 2 Years
RAD 2025: Adults and adolescents treated with nemolizumab experienced rapid onset of action and robust improvements in pruritis, sleep, and quality of life up to 2 years.
Mona Shahriari, MD: Explore the Psychosocial Burden of Atopic Dermatitis with Your Patients—Ask Questions
RAD 2025: Mona Shahriari, MD, underscored the cumulative life impact of atopic dermatitis, reminding clinicians that there is always far more to the condition than meets the clinical eye.
Ruxolitinib Cream Demonstrates Long-Term Safety and Disease Control in Young Patients With Atopic Dermatitis
RAD 2025: In the TRuE-AD3 study, participants aged 2-6 and 7-11 years spent nearly half of the long-term treatment period free of medication.
Nemolizumab Improves Pruritis, Sleep Within 2 Days When Added to Standard Topical Therapy for Atopic Dermatitis
RAD 2025: Nemolizumab as adjunctive therapy to topical steroids with/without topical calcineurin inhibitors provided rapid relief in moderate-to-severe atopic dermatitis.
